Zurich, Switzerland

Simon Mensah Ametamey

This inventor holds 18 USPTO granted patents and 6 published patent applications, plus 7 CIPO patents and 13 EPO patents, primarily in Cannabinoid Receptor Research. Top assignees: ETH Zurich, Hoffmann-La Roche Inc., Merck & Cie. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Simon Mensah Ametamey. Retrieved from https://idiyas.com/inventor/simon-mensah-ametamey

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18 

% Patents Active = 83.3

 

 

Average Co-Inventor Count = 5.2

ph-index = 3

Forward Citations = 24(Granted Patents)


Location History:

  • Zürich, CH (2014)
  • Zurich, CH (2013 - 2024)

Company Filing History:


Years Active: 2013-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Cannabinoid Receptor
Pyridine Compounds
Radiolabeled Ligands
Folate Conjugates
Imaging Agents
Pyrazine Compounds
PET Radiotracers
Azetidine Compounds
Antifolate Analogues
F-saccharide-folates
Agonists
Albumin-binding Entities
18 patents (USPTO):Explore Patents

Title: Simon Mensah Ametamey: A Trailblazer in Pharmaceutical Innovations

Introduction

Simon Mensah Ametamey is a distinguished inventor based in Zurich, Switzerland, with a remarkable portfolio comprising 13 patents. His work primarily focuses on the development of novel compounds that can serve as effective medicaments, particularly in the fields of cannabinoids and radiopharmaceuticals.

Latest Patents

Among his notable inventions, Simon's latest patents include "Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists." This innovation introduces a compound of formula (I), where A, A', and R-R' are specifically defined in the accompanying description and claims. It is noteworthy that this compound has potential medical applications. Another significant patent is "F-saccharide-folates," which pertains to new F-folate radiopharmaceuticals. In this invention, the F isotope is linked through a prosthetic group with a saccharide nature, enhancing its utility in diagnosing and monitoring cancer as well as inflammatory and autoimmune diseases.

Career Highlights

Simon Mensah Ametamey has made significant contributions during his career, having worked with prominent companies such as Merck & Cie and Hoffmann-La Roche Inc. His extensive expertise in pharmaceuticals has played a pivotal role in advancing the science behind therapeutic solutions.

Collaborations

Throughout his career, Simon has collaborated with esteemed professionals in the field, including Rudolf Moser and Viola Groehn. These collaborations have allowed him to harness collective knowledge and drive innovation in his research endeavors.

Conclusion

Simon Mensah Ametamey stands out as a pivotal figure in pharmaceutical innovation, with an impressive array of patents that underline his commitment to developing groundbreaking solutions. His innovative spirit continues to pave the way for advancements in medicinal chemistry and beyond.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…